The Clinical Times
The Front Page of Medicine

Latest medical news · page 47

The latest headlines across every section, pulled from official and open-access sources.

PLOS Medicine · Jun 1, 2026

The NIH 2025 Public Access Policy: Immediate access, unequal costs

by Caitlin R. Ryus, Caroline Raymond King, Edward R. Melnick The NIH 2025 Public Access Policy eliminates embargo periods for federally funded research, expanding who can read science. Yet without addressing article processing charges and market concentration, the policy risks creating new barriers to who can afford to perform and publish their science. In this Perspective, Caitlin Ryus and colleagues discuss the NIH 2025 Public Access Policy, highlighting that while expanding who can read science, the policy risks creating new barriers to who can afford to perform and publish their science.

PLOS Medicine · Jun 1, 2026

Prenatal exposure to asthma medications and risk of neurodevelopmental disorders and educational difficulties: A systematic review and meta-analysis

by Lama A. Shakhshir, Alexia Karain, Jill P. Pell, Claire E. Hastie, Scott M. Nelson, Michael Fleming Background Since asthma exacerbations during pregnancy risk maternal and fetal health, continued medication is important. However, some studies have reported adverse neurodevelopmental outcomes following prenatal exposure to asthma medication. Therefore, this systematic review aimed to collate the existing evidence on the associations between prenatal exposure to asthma medication and neurodevelopmental and educational outcomes. Methods and findings A systematic review was conducted in…

EMA (EU) · May 31, 2026

United for Health: EMA in WorldPride 2026

June is PRIDE month and EMA starts a two-month celebration of diversity and inclusion in science and healthcare, leading up to its participation in the world-famous Amsterdam…, Our strength in the EU comes from our unity in diversity. Equality and non-discrimination are critical everywhere, but in health they can make the difference between…, EMA staff will be joined on the boat by representatives of patient organisations such as EURORDIS-Rare Diseases Europe, European AIDS Treatment Group (EATG) and the European…

WHO · May 31, 2026

Joint statement by the Government of the Democratic Republic of the Congo and WHO concerning the outbreak of Ebola disease caused by the Bundibugyo virus

The Government of the Democratic Republic of the Congo (DRC) and the World Health Organization (WHO) reaffirm their strong partnership and shared commitment to protect the health and well-being of the people of Ituri Province and the nation at large, following the joint mission to Bunia led by Dr Samuel Roger Kamba, Minister of Health, Mr. Patrick Muyaya Katembwe, Minister of Communication and Medias, and the visit of WHO Director-General Dr Tedros Adhanom Ghebreyesus. This high-level visit comes at a challenging time, as the country responds to an outbreak of Ebola disease caused by the…

AFP Podcast (AAFP) · May 31, 2026

Episode 254 | May 2026 | Part 2 American Family Physician

Postoperative management after metabolic surgery (1:30), e-cigarette use (6:30), type II diabetes management (8:10), HIV infection (10:40), preventing falls in older adults (14:20), and nonsteroidal anti-inflammatory drugs for renal colic (18:10).

MedlinePlus (NLM) · May 29, 2026

Necrotizing Skin Infections

Source: Merck & Co., Inc. Related MedlinePlus Pages: Bacterial Infections , Skin Infections

PLOS Medicine · May 29, 2026

Availability, appeal, and addictiveness by design: Tobacco and nicotine industry deliberate targeting of youth

by Raglan Maddox, Becky Freeman, Charlotta Pisinger, Emily Banks Contemporary tobacco and nicotine products, particularly e-cigarettes, are deliberately designed, marketed, and distributed to maximize youth appeal, uptake, dependence, and use. Youth uptake is a predictable outcome of systems designed to maximize product availability, appeal, and addictiveness. In recognition of the World No Tobacco Day 2026 theme, "unmasking the appeal", this Perspective by Raglan Maddox and colleagues discusses how tobacco and nicotine products, particularly e-cigarettes, are deliberately designed and…

PLOS Medicine · May 29, 2026

Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials

by Ellen Jansen, Viki Bockstal, Florence Herschke, Per Olsson Gisleskog, Manuela Rinaldi, Angélique Boerboom, Salah Hadi, Natalia Gaibu, Michel Moutschen, Dominique Tersago Background Variable Heavy domain of Heavy chains (VHH) are innovative tools to target unique epitopes, yet few have been developed as heavy chain-only antibodies for clinical use. Rimteravimab (referred to here as XVR011) is a humanized antibody developed for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19), consisting of two identical VHHs targeting the receptor binding domain (RBD) of the severe acute…

WHO · May 29, 2026

WHO urges governments to protect young people from addiction to tobacco and nicotine products

Worldwide, at least 40 million children aged 13–15 use tobacco products, and young people’s use of e-cigarettes and nicotine pouches continues to rise. In advance of World No Tobacco Day – 31 May – the World Health Organization (WHO) urges governments around the world to protect a new generation from becoming addicted to tobacco and nicotine products.

← NewerOlder →

Back to the live front page